INFINITE BIOMEDICAL TECHNOLOGIES, LLC — Department of Health and Human Services SBIR Phase II: 102
INFINITE BIOMEDICAL TECHNOLOGIES, LLC — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $2,400,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- 102
- Solicitation
- PA11-135
- NAICS
- —
- Place of performance
- MD
- Period
- 2013-03-01 → 2016-08-31
Description
DESCRIPTION provided by applicant There are well over people living with upper limb loss in the United States today and in new amputations are of the upper limb The loss of an upper limb is devastating to a personandapos s quality of life their work productivity and it bring about many psychosocial challenges While there have been exciting technological advances which promise the availability of dexterous prosthetic hands there is a wide gulf between what is technically possible and the reality faced by the overwhelming majority of amputees In short there is a need for an integrated cost effective prosthetic system which can reliably control multiple degrees of freedom In a direct response and in accordance with the scope of PA as related to the development and integration of complex instrumentation we now propose an SBIR Phase IIB effort to develop such a system based on the following innovative solutions the MyoLiner a textile electrode based system for comfortable all day acquisition of multichannel andquot high definitionandquot electromyograms HD EMG the PRO Controller a novel classifier algorithm and associated electronic hardware for decoding intentionality of coordinated hand movements and FlexCells flexible high energy density batteries that are conformal and adaptive to the limb These technologies will be integrated for the first time with dexterous hand technology from our commercial partner to create an affordable highly functional prosthesis the Pattern Recognition Operated Arm PRO Arm The system will be tested in a study designed to evaluate performance on an objective basis as well as from the standpoint of the patient Of note our goal is to have significant clinical impact starting far before the end of the project First we have already launched FlexCells into the market and they have been well received Second we will prepare the MyoLiner system for clinical launch within the first year of the project Third we will build the system in a modular fashion thereby allowing prosthetists to utilize the components with other companiesandapos products Fourth the algorithm development and training is focused on real world performance over the course of the day not just idealized performance in the lab setting And finally fifth the system will be sold to prosthetists well wihin the existing Medicare reimbursement codes thus there should be no financial impediments to clinical adoption of the technology In short we believe that this Phase IIB grant will enable us o bring this project initiated through NIH support to its logical conclusion We will bring the PRO Arm into clinical use an affordable but innovative solution providing significant benefits to uppr extremity amputees PUBLIC HEALTH RELEVANCE The loss of an arm is devastating to almost any individual In this project we will develop and launch a prosthetic limb that will enable intuitive control of a dexterous prosthesis